AMFA-Enzyme Conjugate (Pompe Disease)
Pompe Disease (Lysosomal Storage Disorder)
Key Facts
About NanoMedSyn
NanoMedSyn is a preclinical-stage biotech pioneering a targeted delivery platform based on AMFA glycoligands, which bind to the ubiquitous M6PR. This technology is designed to enhance the tissue targeting, cellular uptake, and lysosomal delivery of a wide range of therapeutic modalities, including antibodies, enzymes, and nanoparticles, potentially creating new classes of degraders and delivery systems. The company has demonstrated preclinical proof-of-concept, notably in Pompe disease where its approach received EMA Orphan Drug Designation, and is led by a team with deep expertise in glycochemistry and drug delivery. Its business model is focused on developing its own therapeutic programs and/or forming platform partnerships with larger biopharmaceutical companies.
View full company profile